Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a Healthcare company (Biotechnology) with a market capitalization of $6.0B. The Maz Rating grades it against the other companies in its sector.
Mirum Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $91.95, Mirum Pharmaceuticals, Inc. trades at 8.9x sales. Over the last twelve months it generated about $676M of revenue and a net loss of $1.0B. It runs a gross margin of 81.7%, an operating margin of -25.3% and a net margin of -134.8%. It shows return on equity of -734.0%, return on invested capital of -22.8% and a free cash flow yield of -8.4%. On the balance sheet: a debt-to-equity ratio of -13.72 and a current ratio of 2.07. Over the past 52 weeks the share price ranged from $63.23 to $130.00, with a beta of 0.49.
Mirum Pharmaceuticals, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 1 Strong Buy and 17 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.